SEPTInvestingStart Free

STIM 8-K: Secondary offering

Neuronetics, Inc.

Filed with the SEC on · accession 0001193125-26-458367

STIM filed a 8-K (current report) with the SEC on Nov 12, 2026. Neuronetics, Inc. entered into an underwriting agreement with William Blair & Company to sell 18,750,000 shares of common stock at $1.60 per share, with an option for underwriters to purchase an additional 2,812,500 shares. The stock moved -11.7% by the first close after the filing.

Summary of the filing

Neuronetics, Inc. entered into an underwriting agreement with William Blair & Company to sell 18,750,000 shares of common stock at $1.60 per share, with an option for underwriters to purchase an additional 2,812,500 shares. The company expects net proceeds of approximately $27.7 million (or $31.9 million if the option is fully exercised), with a portion used to repay term loans under the Perceptive Facility and the remainder for general corporate purposes.

For details, click here →How to read a 8-K →

Key details

Shares of common stock offered (firm)$18.8M
Offering price per share$2
Optional shares for underwriters$2.8M
Estimated net proceeds (without option)$27.7M
Estimated net proceeds (with full option exercise)$31.9M
Outstanding principal under Perceptive Facility as of September 30, 2026$65.0M
Tranche 2 term loans borrowed on August 1, 2025$10.0M
Prepayment of tranche 2 term loans in March 2026$5.0M
UnderwriterWilliam Blair & Company, L.L.C.
Lender under credit agreement and guarantyPerceptive Credit Holdings IV, LP
Legal counsel providing opinionBallard Spahr LLP

How STIM stock reacted

Close before

$1.62

Nov 11, 2026

First close after

-11.73%

$1.43

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for STIM, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for STIM?

Click here

Frequently asked questions

What did STIM file with the SEC on Nov 12, 2026?

STIM filed a 8-K (Secondary offering). Neuronetics, Inc. entered into an underwriting agreement with William Blair & Company to sell 18,750,000 shares of common stock at $1.60 per share, with an option for underwriters to purchase an additional 2,812,500 shares. The company expects net proceeds of approximately $27.7 million (or $31.9 million if the option is fully exercised), with a portion used to repay term loans under the Perceptive Facility and the remainder for general corporate purposes.

What does a secondary offering mean for STIM stock?

New shares dilute existing holders and are often sold at a discount to the market price.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

How did STIM stock react to this filing?

STIM closed at $1.62 before the filing and $1.43 on Nov 12, 2026 (-11.73%).

Other STIM SEC filings

Get alerts when STIM files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
STIM overviewSTIM analysisSTIM newsLatest SEC filings